𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson’s disease

✍ Scribed by Irmgard Paris; Sergio Cardenas; Jorge Lozano; Carolina Perez-Pastene; Rebecca Graumann; Alejandra Riveros; Pablo Caviedes; Juan Segura-Aguilar

Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
825 KB
Volume
12
Category
Article
ISSN
1029-8428

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progression of dopaminergic degeneration
Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study
✍ Walter Pirker; Schiva Djamshidian; Susanne Asenbaum; Willibald Gerschlager; Gott 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

## Abstract Atypical parkinsonian syndromes (APS) such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration are characterized by poor response to antiparkinsonian medication and rapid clinical deterioration. We used SPECT and [^123^I]β‐CIT as a label of dopamine

Dietary restriction and 2-deoxyglucose a
Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease
✍ Wenzhen Duan; Mark P. Mattson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Parkinson's disease (PD) is an age-related disorder characterized by progressive degeneration of dopaminergic neurons in the substantia nigra (SN) and corresponding motor deficits. Oxidative stress and mitochondrial dysfunction are implicated in the neurodegenerative process in PD. Although dietary

Efficacy of piribedil as early combinati
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study
✍ Marc Ziegler; Alexandre Castro-Caldas; Susanna Del Signore; Olivier Rascol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 775 KB

## Abstract Piribedil is a non‐ergot D2/D3 agonist with a significant antagonist action on α2A and α2C adrenergic receptor subtypes. This double‐blind placebo‐controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's dis